At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Rexulti +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.
In Brief
A Phase 2 clinical trial evaluating Rexulti and Placebo for Borderline Personality Disorder. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be tested is that brexpiprazole will be more effective and well tolerated in adults with BPD compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder
CountriesUnited States
CollaboratorsOtsuka America Pharmaceutical
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartNov 2018
Primary CompletionDec 2020
Study CompletionApr 2021
TodayJul 2026
First PostedFeb 1, 2018
Enrollment StartNov 26, 2018
Primary CompletionDec 30, 2020
Study CompletionApr 14, 2021
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 8.4 years ago
Interventions
Rexultidrug
Atypical antipsychotic
Placebodrug
Pill that contains no medicine